Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A randomized, double-blind, parallel-group clinical study was conducted to compare the efficacy, tolerability, and safety of ioversol 320 mg I/mL (Optiray, 320 Mallinckrodt Medical, Inc., St. Louis, MO) and iohexol 300 mg I/mL (Omnipaque 300, Winthrop Pharmaceuticals, New York, NY). The study was conducted in 50 patients undergoing peripheral arteriography and in ten patients undergoing visceral arteriography. In the peripheral group, 92% of the radiographs acquired using Optiray were rated excellent or good. Eighty-eight percent of those acquired with Omnipaque were so rated. In the visceral study all radiographs in both groups were rated excellent or good. Patient tolerance was also impressive. We used a four-point rating scale (1 - none; 4 = severe) to score both heat and pain sensations. For peripheral patients the average heat score was 2.4 in the Optiray group versus 2.3 in the Omnipaque group. The average pain scores were 1.1 in both groups. For visceral patients, the average heat scores were 2.4 in both groups, while the pain scores were 1.7 for the Optiray group versus 1.0 for the Omnipaque group. No clinically significant changes in vital signs were observed in any of the patients. One clinically significant change in the electrocardiogram (ECG) tracing was noted after an Optiray injection, but it was not felt to be drug induced. There were five instances in which laboratory values rose from their normal baseline values, but all changes were minor. There was only one adverse reaction in the entire study. A short episode of coughing occurred in one patient who received Omnipaque for a peripheral study; the coughing resolved spontaneously. Both Optiray and Omnipaque proved to be efficacious, well tolerated, and safe for intra-arterial use in peripheral and visceral vessels.
 ...
PMID:A double-blind comparative study of the safety, tolerability, and efficacy of ioversol and iohexol in peripheral and visceral arteriography. 268 98

Iohexol, a new non-ionic water-soluble contrast medium, was tested for digital intravenous angiography of the cervical and intracranial vessels. In a double blind study involving 40 adult patients, iohexol and meglumine-Na diatrizoate were compared for safety, patient tolerance, and radiographic image quality. Iohexol was shown to be safe and generally produced less patient discomfort, leading to a lower incidence of motion, swallowing or cough artifacts.
 ...
PMID:Comparison of iohexol with meglumine-Na diatrizoate for intravenous digital subtraction angiography. 638 40

The purpose of the present phase IV multicentre trial was to evaluate general patient tolerance to Omnipaque 350 mgI/ml (iohexol) supplied in polypropylene containers compared to that of the same product supplied in routinely used glass vials, with emphasis on allergy-like adverse events. Polypropylene is a pure plastic material with practically no additives, and has been tested in vitro as a contrast medium packaging material for several years. Handling of these containers is easier and safer than handling of glass vials. Iohexol was administered to 1481 patients undergoing urography (741 patients in the glass vial group, 740 in the polypropylene container group), all of whom successfully participated in the trial. Six centres, representing four European countries, participated. Patients were randomized to receive iohexol from either polypropylene containers or traditional glass vials according to a double blind, parallel design. Pre-established inclusion and pre-admission exclusion criteria were followed, as well as routine procedures for preparation of the patients and conduct of the urography examinations at each hospital. Patient tolerance was assessed by recording all adverse events experienced over a period of up to 1 h after the procedure. Allergy-like events were defined as coughing, sneezing, nausea, vomiting, urticaria or itching. No adverse events were experienced by 56.5% of the patients in the glass vial group, nor by 58.0% of those in the polypropylene group. Discomfort (mainly a sensation of warmth) was reported by 39.4% and 38.6% of the patients, and adverse events other than discomfort by 7.4% and 5.9% of the patients, respectively. There seemed to be a correlation between the speed of injection and the frequency of discomfort (an increase with increasing speed), both of which varied a lot between centres. There was no significant difference in the incidence of allergy-like events between the two groups. Such reactions were seen in 2.0% of patients in the glass vial group and 1.9% of those in the polypropylene container group. There was no significant difference between the patients' tolerance to iohexol supplied in traditional glass vials or in polypropylene containers. Therefore, the new polypropylene container can be recommended as a container for Iohexol.
 ...
PMID:Iohexol in patients undergoing urography: a comparison of polypropylene containers (Unique Soft Pack) and glass vials. 783 73

A 49-year-old premenopausal woman presented with acute onset of lower abdominal pain. Physical examination revealed her abdomen was distended and nontender. Her white blood cell count and serum markers for ovarian cancer were normal (alpha-fetoprotein level, 1.6 microg/L; Ca-125 level, 15 U/mL; beta-human chorionic gonadotrophin level < 2 IU/mL). She had no important medical history; in particular, she had no history of malignancy. She denied having any chest symptoms; in particular, she denied experiencing chest pain, cough, or dyspnea. She had stopped smoking at the age of 40 years after having smoked for a total of 20 pack-years. A computed tomographic (CT) examination of the abdomen and pelvis was performed. Helical CT was performed with 150 mL of intravenous contrast material (iohexol, Omnipaque; Amersham Healthcare, Cork, Ireland) and 750 mL of oral contrast material (diatrizoate sodium, Hypaque; Amersham Health, Princeton, NJ). CT sections were 5 mm thick and were acquired from the top of the diaphragm through the ischial tuberosities with a rotation time of 13.5 seconds per rotation and use of a LightSpeed 16 CT scanner (GE Medical Systems, Milwaukee, Wis).
 ...
PMID:Case 116: lymphangioleiomyomatosis. 1758 10